http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013115266-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-191 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0066 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-547 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-87 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-89 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2011-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013115266-A |
| titleOfInvention | APPLICATION OF DESIGN FOR DNA EXPRESSION |
| abstract | 1. The use of a dumbbell-like linear, covalently closed DNA construct with a double-stranded base and single-stranded loops located at both ends of the base, where the base of the complementary deoxyribonucleic acids of the DNA ring chain includes a promoter sequence that encodes a sequence and a termination signal that is introduced by needleless injection to treat cancer. 2. Use according to claim 1, wherein the promoter sequence is operative in eukaryotic cells and in the human body. 3. Use according to claim 1 or 2, wherein the DNA construct encodes immunomodulating agents and / or a cell surface marker. 4. The use according to claim 3, wherein the immunomodulatory agents are selected from the group consisting of antibodies, hormones, cytokines or other biologically active substances. The use according to claim 4, wherein the cytokines are selected from the group consisting of TNF-α, interleukin-7, macrophage granulocyte colony-stimulating factor, CD40L / CD154 and B7.1 / CD806. The use according to claims 1, 2, 4 or 5, wherein the DNA construct is introduced simultaneously or sequentially with a chemotherapeutic agent. 7. The use according to claim 6, wherein the chemotherapeutic agent is selected from the group consisting of antibodies, alkylating agents, platinum analogues, intercalating agents, antibiotics, mitosis suppressors, taxanes, topoisomerase suppressors, antimetabolites and / or L-asparaginase, hydroxycarbamide, mitotans and / or amanitines. 8. Use according to claim 7, wherein the mitosis suppressor is vindesine. 9. Application in accordance with paragraphs 1, 2, |
| priorityDate | 2010-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 104.